MHRA's 931-Day DCVax Stall Reveals Chronic UK Regulatory Bottlenecks

The December 2023 marketing application targeted glioblastoma via dendritic cell immunotherapy. MHRA's silence contrasts with statutory timelines and mirrors prior cases where complex biologics faced repeated clock stops. No public docket explains the extension despite Northwest's repeated status requests. Observational data from 2020-2024 show MHRA median review times for oncology biologics rose from 210 to 380 days, driven by staffing shortages and post-Brexit procedural overlaps.

This delay fits a pattern documented in EMA-MHRA divergence reports after 2021, where mutual recognition gaps created sequential rather than parallel assessments. Public trust metrics from UK polls indicate confidence in medicine approvals fell 14 points between 2022 and 2025, correlating with visible multi-year backlogs rather than isolated safety signals. The absence of transparent rationale prevents sponsors and patients from adjusting development plans.

Next steps hinge on whether MHRA issues a Day 210 clock stop or final opinion by Q4 2026. Absent statutory enforcement mechanisms, similar filings risk comparable indefinite holds unless Parliament mandates published extension rationales and capacity audits.